Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 12/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17009701 | 1.00 | GAA (0.43) | GAAKDM4EIDH1HTTALDH1A1 | |
| SCHEMBL17009707 | 1.00 | GAA (0.43) | GAAKDM4EIDH1HTTALDH1A1 | |
| SCHEMBL18376556 | 0.90 | IDH1 (0.42) | IDH1HTTALDH1A1TDP1 | |
| SCHEMBL18376949 | 0.90 | IDH1 (0.42) | IDH1HTTALDH1A1TDP1 | |
| SCHEMBL20397496 | 0.90 | IDH1 (0.42) | IDH1HTTALDH1A1TDP1 | |
| SCHEMBL18376557 | 0.90 | IDH1 (0.42) | IDH1HTTALDH1A1TDP1 | |
| SCHEMBL18376948 | 0.90 | IDH1 (0.42) | IDH1HTTALDH1A1TDP1 | |
| SCHEMBL17010514 | 0.87 | IDH1 (0.39) | GAAKDM4EIDH1HTTALDH1A1 | |
| SCHEMBL17010504 | 0.87 | IDH1 (0.39) | GAAKDM4EIDH1HTTALDH1A1 | |
| SCHEMBL17010516 | 0.87 | IDH1 (0.39) | GAAKDM4EIDH1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3319945-B1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2021-04-28 | — | — | EP | disclosed |
| EP-3322694-B1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2020-02-19 | — | — | EP | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-15 | — | — | US | disclosed |
| US-10414734-B2 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-17 | — | — | US | disclosed |
| US-10414734-B2 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-17 | — | — | US | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3105209-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3105210-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM, STIFTUNG DES ÖFFENTLICHEN RECHTS (DE) | 2017-07-13 | — | — | US | disclosed |
| WO-2017009325-A1 | 5-HYDROXYALKYLBENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017005674-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017005674-A1 | 2-ARYL- AND 2-ARYLALKYL-BENZIMIDAZOLES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414734-B2 | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors | HRH1, HRH2, MDN1 | GAA 1791/4885KDM4E 1360/4885IDH1 75/4885 |
| US-10442772-B2 | Benzimidazol-2-amines as mIDH1 inhibitors | HRH1, HRH2, HRH3 | GAA 1666/4885KDM4E 1923/4885IDH1 173/4885 |
| US-20170197921-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | GAA 1666/4885KDM4E 1923/4885IDH1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.